Christopher Freeman compensation by year
Guardant Health Summary Compensation Table · all 3 fiscal years held| Component | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Salary | $249,231 | $468,269 | $490,385 |
| Bonus | $300,000 | $0 | $0 |
| Stock awards | $2,156,323 | $1,456,309 | $1,621,395 |
| Option awards | $2,539,902 | $1,882,865 | $1,075,387 |
| Non-equity incentive | $183,938 | $152,760 | $327,443 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $7,056 | $9,364 | $8,442 |
| Total | $5,436,449 | $3,969,567 | $3,523,052 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Guardant Health, Inc. DEF 14A filed April 25, 2024, accession 0001193125-24-113951, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Guardant Health, Inc. filed document, accession 0001193125-24-113951. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 23,141 | $625,964 | — |
| RSU | 19,907 | $538,484 | — |
| RSU | 16,738 | $452,763 | — |
| PSU | 15,428 | $417,327 | — |
| RSU | 9,758 | $263,954 | — |
| PSU | 7,713 | $208,637 | — |
| Option | 14,638 | — | $110.49 |
| Option | 43,710 | — | $47.20 |
| Option | 25,107 | — | $32.86 |
| Option | 29,861 | — | $28.37 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Guardant Health, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Guardant Health discloses, by trigger · FY2020| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $712,500 | $1,237,355 | $32,468 | $1,982,323 |
| Disability | — | — | — | $1,736,000 |
| Involuntary termination without cause | $237,500 | — | $16,234 | $253,734 |
Per the Potential Payments Upon Termination or Change in Control table in Guardant Health, Inc.'s FY2020 proxy. Estimates as the company printed them; a dash means it printed no figure.
Guardant Health’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Ines Dahne-Steuber | Former Chief Operating Officer (a) | $5,836,716 |
| Darya Chudova | Chief Technology Officer | $4,755,541 |
| Michael Bell | Chief Financial Officer | $4,123,993 |
| Christopher Freeman · this page | Chief Commercial Officer | $3,523,052 |
| Craig Eagle | Chief Medical Officer | $3,485,356 |
| John Saia | Chief Legal Officer | $2,980,104 |
| AmirAli Talasaz | Co-Chief Executive Officer | $26,415 |
| Helmy Eltoukhy | Chairman and Co-Chief Executive Officer | $11,591 |
The full Guardant Health compensation record
free company briefThis page is one person within Guardant Health's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Guardant Health proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Guardant Health's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.